Wright’s Stringer Archive

STRINGER ENTRY #1

Can a Pill Really Give You the Benefits of Exercise?

Stringer Scale: Early Catch

Researchers are studying compounds that imitate some biological signals triggered by exercise. One compound behind recent headlines is SLU-PP-332, which activated exercise-related metabolic pathways and improved endurance in mouse studies.

That is interesting research, but it is not an exercise replacement. SLU-PP-332 has not been established as safe or effective in people, is not an FDA-approved exercise medication, and has not been shown to reproduce the broad cardiovascular, musculoskeletal, metabolic, neurologic, and functional benefits of physical activity.

THE FOUNDER’S VERDICT

The laboratory concept is promising, particularly as a possible future approach for people unable to exercise normally because of illness, paralysis, frailty, muscle disease, or prolonged bed rest. For now, claims that a pill can provide the full benefits of exercise run well ahead of the human evidence.

Sources: Original SLU-PP-332 research | PubMed record | FDA performance-product warning

STRINGER ENTRY #2

What If the Hole Left by a Stroke Could Become a Place to Regrow the Brain?

For decades, medicine has raced to save the brain during a stroke. Researchers at Duke are asking a very different question: What if we could repair some of the brain after the damage has already occurred?

When someone suffers an ischemic stroke, the clock starts immediately.

Restore the blood flow. Save the penumbra. Preserve as many neurons as possible.

Modern thrombolysis and mechanical thrombectomy have transformed our ability to do that.

But there is a line medicine has largely been unable to cross.

Once brain tissue is dead, we cannot put it back.

The infarcted tissue eventually leaves behind an area of profound tissue loss—a cavity surrounded by inflammation, gliosis, and surviving neural tissue attempting to reorganize around the injury.

We rehabilitate the patient. We encourage the surviving brain to adapt. But we do not rebuild the missing brain.

At least, not yet.

Someone Looked at the Hole Differently

A research team led by biomedical engineer Tatiana Segura at Duke University, working with stroke researcher S. Thomas Carmichael and colleagues, has been developing an entirely different approach.

Instead of viewing the post-stroke cavity simply as evidence of irreversible destruction, they asked whether that empty space could become a construction site for repair.

Their 2026 experiment, published in Cell Biomaterials, used a microporous annealed particle scaffold—or MAPS.

Picture thousands of microscopic hydrogel particles being injected into the damaged area and assembling into a three-dimensional porous framework.

Not replacement brain.

Scaffolding.

Much like the temporary structure erected around a damaged building, its job is to create an environment into which the body’s own cells can move.

The Scaffold Carries Messages

Astrocytes—the star-shaped cells abundant throughout the central nervous system—communicate partly through microscopic packages called extracellular vesicles, or EVs. These vesicles contain biologically active cargo capable of influencing other cells.

The researchers activated astrocytes using different combinations of signaling molecules and attached their extracellular vesicles directly to the hydrogel particles. One combination was particularly interesting: IL-4 + C1q.

Those EVs appeared to change what happened inside the damaged brain. Rather than simply filling the cavity, the EV-loaded scaffold helped create what the researchers describe as a regenerative immune niche.

Blood Vessels Began Growing Into the Infarct

The researchers induced ischemic strokes in mice.

Five days later—after the necrotic infarct core had formed—they injected the experimental scaffold directly into the stroke cavity.

Within nine days, perfused microvessels had formed in the center of the infarct. The researchers also observed vascular remodeling and axonal sprouting or remodeling around the damaged region.

By eight weeks, mice receiving the optimized IL-4/C1q EV-MAPS treatment showed motor performance approaching their pre-stroke baseline on the study’s behavioral testing.

That is impressive. But perhaps the most fascinating part of the experiment was not the hydrogel.

It was the immune system.

An Unexpected Repair Crew

Most physicians were taught to think of neutrophils arriving after tissue injury primarily as inflammatory first responders. In acute stroke, that reputation is well deserved.

But biology rarely fits neatly into the categories we give it.

The scaffold carrying IL-4/C1q-conditioned astrocyte EVs selectively recruited macrophages and neutrophils into the infarct.

The researchers then depleted the neutrophils.

The angiogenic response disappeared.

In other words, in this experimental setting, the neutrophils were not merely bystanders accompanying repair. They were required for the new blood-vessel formation the investigators observed.

We are beginning to understand that inflammation is not simply something medicine should suppress. Sometimes the challenge may be learning how to redirect it.

Now Comes the Important Part

Nobody has regenerated a human brain after stroke with this technology.

Nobody has shown that injecting this scaffold into a human stroke cavity restores lost neurologic function. There is no FDA-approved MAPS treatment for stroke, and this material has not yet been tested in a human clinical trial for this purpose.

The findings are from mice. Additional safety work and studies in larger, more clinically representative stroke models are needed before human testing could be considered.

There are enormous translational questions ahead:

• Will the same immune response occur in humans?
• How safe is intracerebral implantation?
• How large an infarct could realistically be treated?
• What is the optimal treatment window?
• Could new vascular and neural growth produce unintended consequences?
• Does anatomical repair ultimately translate into meaningful, durable human neurological recovery?

We do not know.

That distinction matters. But it does not make this research less exciting.

It makes it science.

THE STRINGER

There is a bigger idea hiding inside this experiment.

For most of modern stroke medicine, we have been fighting a defensive battle: save what can still be saved.

Thrombolysis does that. Thrombectomy does that. Neurocritical care does that. Rehabilitation then teaches the remaining nervous system to compensate for what could not be saved.

This research suggests the possibility of adding another phase someday:

Rebuild.

Not by manufacturing a new piece of brain in a laboratory and implanting it. Instead, perhaps we can construct an environment inside damaged tissue that gives the body’s own vascular, immune, and neural systems somewhere—and some reason—to begin repairing it.

That is a fundamentally different way of thinking about stroke.

If scientists eventually learn how to turn an infarct cavity from a biologically hostile void into an environment capable of supporting organized repair, where else might that strategy work?

Traumatic brain injury? Spinal cord injury? Neurodegenerative disease?

We do not know.

Stringer Scale: Early Catch — Compelling preclinical findings, but not yet tested in people.

Today’s mouse experiment is not tomorrow’s treatment. But occasionally, buried inside an experiment like this, you can see medicine beginning to ask a question it could not seriously ask before.

And this time the question is extraordinary:

What if dead brain tissue did not always have to be the end of the story?

— Milton Wright, DO, FACOFP
Founding Director
Founders Institute of Medicine & Education

Sources: Original 2026 study in Cell Biomaterials | Earlier MAP hydrogel stroke research | Duke University research summary

Dr. Wright’s Stringer explores emerging medical science and technology. This article discusses preclinical research and is intended for education, not as medical advice or a representation of an available treatment.